JP7189141B2 - Ｔ細胞エンゲージ抗体コンストラクトを含む低ｐＨ医薬組成物 - Google Patents

Ｔ細胞エンゲージ抗体コンストラクトを含む低ｐＨ医薬組成物 Download PDF

Info

Publication number
JP7189141B2
JP7189141B2 JP2019541303A JP2019541303A JP7189141B2 JP 7189141 B2 JP7189141 B2 JP 7189141B2 JP 2019541303 A JP2019541303 A JP 2019541303A JP 2019541303 A JP2019541303 A JP 2019541303A JP 7189141 B2 JP7189141 B2 JP 7189141B2
Authority
JP
Japan
Prior art keywords
domain
antibody
pharmaceutical composition
seq
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019541303A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020506924A (ja
JP2020506924A5 (enExample
Inventor
マコーリー，アーノルド
ガティベンカタクリシュナ，パバン
アベル，ジェフ
ホ，ジュン
ポンペ，コーネリアス
カナプラン，セカール
トロイハイト，ミヒャエル
ジャガンナサン，バラディワジ
Original Assignee
アムジェン リサーチ （ミュニック） ゲゼルシャフト ミット ベシュレンクテル ハフツング
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジェン リサーチ （ミュニック） ゲゼルシャフト ミット ベシュレンクテル ハフツング, アムジエン・インコーポレーテツド filed Critical アムジェン リサーチ （ミュニック） ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2020506924A publication Critical patent/JP2020506924A/ja
Publication of JP2020506924A5 publication Critical patent/JP2020506924A5/ja
Priority to JP2022192672A priority Critical patent/JP2023022235A/ja
Application granted granted Critical
Publication of JP7189141B2 publication Critical patent/JP7189141B2/ja
Priority to JP2024069493A priority patent/JP2024099682A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2019541303A 2017-02-02 2018-02-02 Ｔ細胞エンゲージ抗体コンストラクトを含む低ｐＨ医薬組成物 Active JP7189141B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022192672A JP2023022235A (ja) 2017-02-02 2022-12-01 Ｔ細胞エンゲージ抗体コンストラクトを含む低ｐＨ医薬組成物
JP2024069493A JP2024099682A (ja) 2017-02-02 2024-04-23 Ｔ細胞エンゲージ抗体コンストラクトを含む低ｐＨ医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762453952P 2017-02-02 2017-02-02
US62/453,952 2017-02-02
PCT/EP2018/052665 WO2018141910A1 (en) 2017-02-02 2018-02-02 Low ph pharmaceutical composition comprising t cell engaging antibody constructs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022192672A Division JP2023022235A (ja) 2017-02-02 2022-12-01 Ｔ細胞エンゲージ抗体コンストラクトを含む低ｐＨ医薬組成物

Publications (3)

Publication Number Publication Date
JP2020506924A JP2020506924A (ja) 2020-03-05
JP2020506924A5 JP2020506924A5 (enExample) 2021-01-28
JP7189141B2 true JP7189141B2 (ja) 2022-12-13

Family

ID=61274222

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019541303A Active JP7189141B2 (ja) 2017-02-02 2018-02-02 Ｔ細胞エンゲージ抗体コンストラクトを含む低ｐＨ医薬組成物
JP2022192672A Pending JP2023022235A (ja) 2017-02-02 2022-12-01 Ｔ細胞エンゲージ抗体コンストラクトを含む低ｐＨ医薬組成物
JP2024069493A Pending JP2024099682A (ja) 2017-02-02 2024-04-23 Ｔ細胞エンゲージ抗体コンストラクトを含む低ｐＨ医薬組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022192672A Pending JP2023022235A (ja) 2017-02-02 2022-12-01 Ｔ細胞エンゲージ抗体コンストラクトを含む低ｐＨ医薬組成物
JP2024069493A Pending JP2024099682A (ja) 2017-02-02 2024-04-23 Ｔ細胞エンゲージ抗体コンストラクトを含む低ｐＨ医薬組成物

Country Status (39)

Country Link
US (2) US12617853B2 (enExample)
EP (3) EP3576788B1 (enExample)
JP (3) JP7189141B2 (enExample)
KR (3) KR20250134211A (enExample)
CN (1) CN110582297B (enExample)
AR (1) AR110955A1 (enExample)
AU (3) AU2018214223B2 (enExample)
BR (1) BR112019016104A2 (enExample)
CA (1) CA3052098A1 (enExample)
CL (1) CL2019002178A1 (enExample)
CO (1) CO2019009480A2 (enExample)
CR (1) CR20190408A (enExample)
DK (1) DK3576788T3 (enExample)
EA (1) EA201991769A1 (enExample)
ES (1) ES3040289T3 (enExample)
FI (1) FI3576788T3 (enExample)
HR (1) HRP20250830T1 (enExample)
HU (1) HUE072190T2 (enExample)
IL (3) IL321314A (enExample)
JO (2) JOP20190189B1 (enExample)
LT (1) LT3576788T (enExample)
MA (1) MA47425B1 (enExample)
MD (1) MD3576788T2 (enExample)
MX (3) MX2019009133A (enExample)
MY (1) MY201516A (enExample)
NZ (1) NZ756016A (enExample)
PE (1) PE20200153A1 (enExample)
PH (1) PH12019501796A1 (enExample)
PL (1) PL3576788T3 (enExample)
PT (1) PT3576788T (enExample)
RS (1) RS67174B1 (enExample)
SA (1) SA519402365B1 (enExample)
SG (1) SG11201907048UA (enExample)
SI (1) SI3576788T1 (enExample)
SM (1) SMT202500367T1 (enExample)
TN (1) TN2019000225A1 (enExample)
TW (1) TWI840325B (enExample)
WO (1) WO2018141910A1 (enExample)
ZA (1) ZA201905674B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024099682A (ja) * 2017-02-02 2024-07-25 アムジェン リサーチ （ミュニック） ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｔ細胞エンゲージ抗体コンストラクトを含む低ｐＨ医薬組成物

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA039859B1 (ru) * 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
AR107582A1 (es) 2016-02-03 2018-05-16 Amgen Res Munich Gmbh Constructos de anticuerpo biespecíficos para psma y cd3 que se ligan a células t
EP3559035A1 (en) 2016-12-21 2019-10-30 TeneoBio, Inc. Anti-bcma heavy chain-only antibodies
SG11202013248YA (en) * 2018-07-31 2021-02-25 Amgen Inc Pharmaceutical formulations of masked antibodies
MX2021003976A (es) 2018-10-11 2021-05-27 Amgen Inc Procesamiento posterior de constructos de anticuerpos biespecificos.
WO2021091906A1 (en) 2019-11-04 2021-05-14 Amgen Inc. Methods for treating leukemia
AU2020395148A1 (en) * 2019-12-06 2022-06-23 Theratechnologies Inc. Sortilin binding conjugate compounds, compositions and uses thereof for treating cancer
AU2021263813A1 (en) 2020-04-29 2022-10-27 Amgen Inc. Pharmaceutical formulation
IL297081A (en) * 2020-04-29 2022-12-01 Amgen Inc Pharmaceutical formulation
CA3184351A1 (en) * 2020-06-04 2021-12-09 Amgen Inc. Bispecific binding constructs
EP4200333A1 (en) * 2020-08-24 2023-06-28 Amgen Inc. Pharmaceutical formulation comprising a bite, bispecific antibody, and methionine
WO2022060878A1 (en) 2020-09-16 2022-03-24 Amgen Inc. Methods for treating prostate cancer
AU2021345124A1 (en) 2020-09-16 2023-03-30 Amgen Inc. Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer
CA3200317A1 (en) * 2020-11-06 2022-05-12 Amgen Inc. Multitargeting bispecific antigen-binding molecules of increased selectivity
JP2023550148A (ja) 2020-11-20 2023-11-30 シンシア・イノベーション・インコーポレイテッド がん免疫治療に用いられる武装二重ｃａｒ－ｔ組成物及び方法
WO2023183231A1 (en) 2022-03-21 2023-09-28 Amgen Inc. Combination therapy methods with t-cell engaging molecules for treatment of prostate cancer
EP4598958A1 (en) 2022-10-05 2025-08-13 Amgen Inc. Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
TW202602940A (zh) 2024-04-09 2026-01-16 美商安進公司 激動性抗ｉｌ－２ｒｂｇ重鏈抗體

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010505852A (ja) 2006-10-06 2010-02-25 アムジエン・インコーポレーテツド 安定な抗体製剤
JP2011504933A (ja) 2007-11-28 2011-02-17 メディミューン，エルエルシー タンパク質製剤
WO2016036678A1 (en) 2014-09-02 2016-03-10 Medimmune, Llc Formulations of bispecific antibodies

Family Cites Families (188)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013A (en) 1847-03-13 Improvement in apparatus for the manufacture of malleable iron
US556A (en) 1838-01-09 Machine foe
US3180193A (en) 1963-02-25 1965-04-27 Benedict David Machines for cutting lengths of strip material
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
SE425364B (sv) * 1977-06-29 1982-09-27 Stille Werner Ab Instrument av saxtyp
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4694778A (en) 1984-05-04 1987-09-22 Anicon, Inc. Chemical vapor deposition wafer boat
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
EP0320015B1 (en) 1987-12-09 1994-07-20 Omron Tateisi Electronics Co. Inductive data communicating apparatus
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2090473A1 (en) 1990-08-29 1992-03-01 Robert M. Kay Homologous recombinatin in mammalian cells
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
JPH04154298A (ja) 1990-10-17 1992-05-27 Pioneer Electron Corp スピーカ装置
DK0575319T3 (da) 1991-03-11 2000-07-10 Univ Georgia Res Found Kloning og ekspression af Renilla-luciferase
US5834229A (en) 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
WO1992022670A1 (en) 1991-06-12 1992-12-23 Genpharm International, Inc. Early detection of transgenic embryos
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
WO1994000569A1 (en) 1992-06-18 1994-01-06 Genpharm International, Inc. Methods for producing transgenic non-human animals harboring a yeast artificial chromosome
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5981175A (en) 1993-01-07 1999-11-09 Genpharm Internation, Inc. Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2169298A1 (en) 1993-09-10 1995-03-16 Martin Chalfie Uses of green fluorescent protein
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
EP0773288A3 (en) 1995-08-29 1997-07-09 Kirin Brewery Chimera animal and its method of manufacture
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
GB9623935D0 (en) 1996-11-18 1997-01-08 Unilever Plc Aqueous cleansing composition
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
ATE290205T1 (de) 1996-12-12 2005-03-15 Prolume Ltd Vorrichtung und verfahren zum nachweis und identifizieren von infektiösen wirkstoffen
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
AU765703B2 (en) 1998-03-27 2003-09-25 Bruce J. Bryan Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
CA2326389C (en) 1998-04-21 2007-01-23 Micromet Gesellschaft Fur Biomedizinische Forschung Mbh Novel cd19xcd3 specific polypeptides and uses thereof
ES2207278T3 (es) 1998-07-28 2004-05-16 Micromet Ag Heterominicuerpos.
US7254167B2 (en) 1998-10-30 2007-08-07 Broadcom Corporation Constellation-multiplexed transmitter and receiver
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
AU2001264946A1 (en) 2000-05-24 2001-12-03 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
US6297958B1 (en) * 2000-05-26 2001-10-02 General Bandwidth Inc. System and method for housing telecommunications equipment
US7230167B2 (en) 2001-08-31 2007-06-12 Syngenta Participations Ag Modified Cry3A toxins and nucleic acid sequences coding therefor
ES2645563T3 (es) 2001-11-30 2017-12-05 Amgen Fremont Inc. Animales transgénicos que portan genes de cadena ligera de Ig humana
DE10211800A1 (de) 2002-03-16 2003-10-02 Deere & Co Einrichtung zur Erfassung des Vorhandenseins eines Gutstroms in einer Erntemaschine
US8486859B2 (en) 2002-05-15 2013-07-16 Bioenergy, Inc. Use of ribose to enhance plant growth
US7904068B2 (en) 2003-06-06 2011-03-08 At&T Intellectual Property I, L.P. System and method for providing integrated voice and data services utilizing wired cordless access with unlicensed spectrum and wired access with licensed spectrum
US8076459B2 (en) 2003-10-16 2011-12-13 Micromet Ag Multispecfic deimmunized CD3-binders
EP1786918A4 (en) 2004-07-17 2009-02-11 Imclone Systems Inc NEW BISPECIFIC ANTIBODY TETRAVALENT
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EP1703348B1 (en) 2005-03-14 2010-10-13 Omron Corporation Programmable controller system
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
US8234145B2 (en) 2005-07-12 2012-07-31 International Business Machines Corporation Automatic computation of validation metrics for global logistics processes
BRPI0604215A (pt) 2005-08-17 2007-04-10 Biosigma Sa método para projetar oligonucleotìdeos para técnicas de biologia molecular
US8236308B2 (en) 2005-10-11 2012-08-07 Micromet Ag Composition comprising cross-species-specific antibodies and uses thereof
JP2007122396A (ja) 2005-10-27 2007-05-17 Hitachi Ltd ディスクアレイ装置及びその障害対応検証方法
US7919297B2 (en) 2006-02-21 2011-04-05 Cornell Research Foundation, Inc. Mutants of Aspergillus niger PhyA phytase and Aspergillus fumigatus phytase
US7574748B2 (en) 2006-03-07 2009-08-18 Nike, Inc. Glove with support system
US7990860B2 (en) 2006-06-16 2011-08-02 Harris Corporation Method and system for rule-based sequencing for QoS
US8430938B1 (en) 2006-07-13 2013-04-30 The United States Of America As Represented By The Secretary Of The Navy Control algorithm for autothermal reformer
GB0614780D0 (en) * 2006-07-25 2006-09-06 Ucb Sa Biological products
KR101146588B1 (ko) 2006-08-11 2012-05-16 삼성전자주식회사 Ｆｉｎ 구조체 및 이를 이용한 핀 트랜지스터의 제조방법
CN100589507C (zh) 2006-10-30 2010-02-10 华为技术有限公司 一种拨号提示系统及方法
US7466008B2 (en) 2007-03-13 2008-12-16 Taiwan Semiconductor Manufacturing Company, Ltd. BiCMOS performance enhancement by mechanical uniaxial strain and methods of manufacture
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
CA2697922A1 (en) 2007-08-28 2009-03-12 Biogen Idec Ma Inc. Compositions that bind multiple epitopes of igf-1r
US8209741B2 (en) 2007-09-17 2012-06-26 Microsoft Corporation Human performance in human interactive proofs using partial credit
US8464584B2 (en) 2007-10-19 2013-06-18 Food Equipment Technologies Company, Inc. Beverage dispenser with level measuring apparatus and display
DE102008057648A1 (de) 2007-11-29 2009-06-04 Luk Lamellen Und Kupplungsbau Beteiligungs Kg Kraftübertragungsvorrichtung, insbesondere zur Leistungsübertragung zwischen einer Antriebsmaschine und einem Abtrieb
US8376279B2 (en) 2008-01-23 2013-02-19 Aurora Flight Sciences Corporation Inflatable folding wings for a very high altitude aircraft
AU2009299794B2 (en) 2008-10-01 2015-08-13 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
EP2404668B1 (en) 2009-03-04 2014-05-07 Nissan Motor Co., Ltd. Exhaust gas purification catalyst and process for producing same
US8463191B2 (en) 2009-04-02 2013-06-11 Qualcomm Incorporated Beamforming options with partial channel knowledge
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
AR080154A1 (es) * 2010-02-10 2012-03-14 Immunogen Inc Anticuerpos cd20 y su utilizacion
EP2658739B1 (de) 2010-12-30 2017-02-22 Johnson Controls Metals and Mechanisms GmbH & Co. KG Längsverstellvorrichtung eines kraftfahrzeugsitzes mit zwei schienenpaaren
WO2013026837A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
LT2748201T (lt) 2011-08-23 2018-02-26 Roche Glycart Ag Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė
WO2013113615A1 (en) * 2012-02-03 2013-08-08 F. Hoffmann-La Roche Ag Bispecific antibody molecules with antigen-transfected t-cells and their use in medicine
JO3519B1 (ar) * 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
WO2014151910A1 (en) 2013-03-15 2014-09-25 Amgen Inc. Heterodimeric bispecific antibodies
WO2015048272A1 (en) 2013-09-25 2015-04-02 Amgen Inc. V-c-fc-v-c antibody
LT3074424T (lt) * 2013-11-27 2025-05-26 Zymeworks Bc Inc. Bispecifiniai antigeną surišantys konstruktai, nukreipti į her2
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof
US10105142B2 (en) 2014-09-18 2018-10-23 Ethicon Llc Surgical stapler with plurality of cutting elements
PL3283524T3 (pl) * 2015-04-17 2023-06-12 Amgen Research (Munich) Gmbh Konstrukty biswoistego przeciwciała dla cdh3 i cd3
EA039859B1 (ru) * 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI796283B (zh) * 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
JOP20170017B1 (ar) * 2016-01-25 2021-08-17 Amgen Res Munich Gmbh تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
AR107582A1 (es) * 2016-02-03 2018-05-16 Amgen Res Munich Gmbh Constructos de anticuerpo biespecíficos para psma y cd3 que se ligan a células t
UA126657C2 (uk) * 2016-02-03 2023-01-11 Емджен Рісерч (Мюнік) Ґмбг ОДНОЛАНЦЮГОВА КОНСТРУКЦІЯ АНТИТІЛА ДО BCMA І CD3<font face="Symbol">e</font>
CR20190408A (es) * 2017-02-02 2020-01-31 Amgen Inc Composición farmacéutica de bajo ph que comprende construcciones de anticuerpos que activan linfocitos t antecedentes
TW201940518A (zh) * 2017-12-29 2019-10-16 美商安進公司 針對ｍｕｃ１７和ｃｄ３之雙特異性抗體構建體
EP3749363A1 (en) * 2018-02-08 2020-12-16 Amgen Inc. Low ph pharmaceutical antibody formulation
SG11202013248YA (en) * 2018-07-31 2021-02-25 Amgen Inc Pharmaceutical formulations of masked antibodies
BR112021002032A2 (pt) * 2018-08-03 2021-07-20 Amgen Research (Munich) Gmbh construtos de anticorpos para cldn18.2 e cd3
WO2020072306A1 (en) * 2018-10-01 2020-04-09 Amgen Inc. Methods for reducing aggregation of bispecific antibodies
WO2021089748A2 (en) * 2019-11-06 2021-05-14 Amgen Research (Munich) Gmbh Multitargeting antigen-binding molecules for use in proliferative diseases
AU2021263813A1 (en) * 2020-04-29 2022-10-27 Amgen Inc. Pharmaceutical formulation
US10888634B1 (en) * 2020-09-28 2021-01-12 Ideal Jacobs Corp. Systems and methods for atomizing liquids
CA3200317A1 (en) * 2020-11-06 2022-05-12 Amgen Inc. Multitargeting bispecific antigen-binding molecules of increased selectivity
TW202225188A (zh) * 2020-11-06 2022-07-01 德商安美基研究（慕尼黑）公司 與ｃｄ３結合的多肽構建體
MX2023012931A (es) * 2021-05-06 2023-11-13 Amgen Res Munich Gmbh Moleculas de union a antigeno dirigidas a cd20 y cd22 para su uso en enfermedades proliferativas.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010505852A (ja) 2006-10-06 2010-02-25 アムジエン・インコーポレーテツド 安定な抗体製剤
JP2011504933A (ja) 2007-11-28 2011-02-17 メディミューン，エルエルシー タンパク質製剤
WO2016036678A1 (en) 2014-09-02 2016-03-10 Medimmune, Llc Formulations of bispecific antibodies

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BINYAM BEZABEH，MABS，2016年12月16日，VOL:9, NR:2，PAGE(S):240 - 256
KARIN TAYLOR，ENGINEERING BISPECIFIC ANTIBODIES FOR TARGETED DELIVERY OF CYTOTOXIN- LOADED NANOPARTICLES TO TUMOUR CELLS，A thesis submitted for the degree of Doctor of Philosophy at The University of Queensland in 2015, The Australian Institute for Bioengineering and Nanotechnology (AIBN)，2015年，PAGE(S):I-XVII,1-148
PETRA MATT，THE ONCOLOGIST，2011年，VOL:16，PAGE(S):1451-1457
VON KREUDENSTEIN THOMAS SPRETER，MABS，2013年，VOL:5, NR:5，PAGE(S):646 - 654

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024099682A (ja) * 2017-02-02 2024-07-25 アムジェン リサーチ （ミュニック） ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｔ細胞エンゲージ抗体コンストラクトを含む低ｐＨ医薬組成物

Also Published As

Publication number Publication date
EP4620975A3 (en) 2025-12-24
KR20240055865A (ko) 2024-04-29
MX2025002707A (es) 2025-04-02
US20200332000A1 (en) 2020-10-22
SMT202500367T1 (it) 2025-11-10
JOP20190189A1 (ar) 2019-08-01
IL319311A (en) 2025-04-01
HUE072190T2 (hu) 2025-10-28
EP4620976A2 (en) 2025-09-24
FI3576788T3 (fi) 2025-08-29
CA3052098A1 (en) 2018-08-09
PL3576788T3 (pl) 2025-11-12
BR112019016104A2 (pt) 2020-04-14
ES3040289T3 (en) 2025-10-29
SA519402365B1 (ar) 2024-01-15
IL268351B2 (en) 2025-11-01
MA47425A (fr) 2019-12-11
JOP20250206A1 (ar) 2025-08-12
IL268351A (en) 2019-09-26
SG11201907048UA (en) 2019-08-27
KR102658637B1 (ko) 2024-04-19
TW202502381A (zh) 2025-01-16
IL268351B1 (en) 2025-07-01
MX2019009133A (es) 2019-12-19
JP2023022235A (ja) 2023-02-14
SI3576788T1 (sl) 2025-08-29
MY201516A (en) 2024-02-27
EP3576788B1 (en) 2025-06-25
CO2019009480A2 (es) 2019-09-18
PH12019501796A1 (en) 2019-09-16
US20250368737A1 (en) 2025-12-04
AU2025208560A1 (en) 2025-08-28
LT3576788T (lt) 2025-08-11
IL321314A (en) 2025-08-01
JOP20190189B1 (ar) 2025-10-01
KR102853228B1 (ko) 2025-09-03
AR110955A1 (es) 2019-05-22
AU2025208561A1 (en) 2025-08-28
HRP20250830T1 (hr) 2025-09-12
DK3576788T3 (da) 2025-09-08
MA47425B1 (fr) 2025-09-30
KR20250134211A (ko) 2025-09-09
WO2018141910A1 (en) 2018-08-09
CN110582297A (zh) 2019-12-17
US12617853B2 (en) 2026-05-05
TW201900209A (zh) 2019-01-01
EP4620976A3 (en) 2025-12-24
NZ756016A (en) 2022-07-01
JP2020506924A (ja) 2020-03-05
CR20190408A (es) 2020-01-31
AU2018214223B2 (en) 2025-08-14
TWI840325B (zh) 2024-05-01
PE20200153A1 (es) 2020-01-17
TN2019000225A1 (en) 2021-01-07
ZA201905674B (en) 2020-10-28
EP4620975A2 (en) 2025-09-24
RS67174B1 (sr) 2025-09-30
EA201991769A1 (ru) 2020-07-29
JP2024099682A (ja) 2024-07-25
EP3576788A1 (en) 2019-12-11
CN110582297B (zh) 2024-07-30
CL2019002178A1 (es) 2020-09-21
AU2018214223A1 (en) 2019-08-15
MD3576788T2 (ro) 2025-12-31
KR20190137077A (ko) 2019-12-10
MX2024004337A (es) 2024-04-24
PT3576788T (pt) 2025-09-09

Similar Documents

Publication Publication Date Title
JP7295916B2 (ja) Ｐｓｍａおよびｃｄ３に対する二重特異性を有するｔ細胞エンゲージ抗体コンストラクト
US20250368737A1 (en) Low ph pharmaceutical composition comprising t cell engaging antibody constructs
TWI754628B (zh) 雙特異性t細胞嚙合抗體構築體
JP7605913B2 (ja) Ｍｕｃ１７及びｃｄ３に向けられる二重特異性抗体コンストラクト
US20260083841A1 (en) Bispecific Molecule Stabilizing Composition
HK40130469A (en) Low ph pharmaceutical composition comprising t cell engaging antibody constructs
HK40130468A (en) Low ph pharmaceutical composition comprising t cell engaging antibody constructs
HK40018569A (en) Low ph pharmaceutical composition comprising t cell engaging antibody constructs
HK40018569B (en) Low ph pharmaceutical composition comprising t cell engaging antibody constructs
HK1257749B (en) Psma and cd3 bispecific t cell engaging antibody constructs

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220704

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221101

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221201

R150 Certificate of patent or registration of utility model

Ref document number: 7189141

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150